GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells-Reference-Cited by-同舟云学术

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Published:2019-03-27 Issue:485 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Smith Eric L.¹²^ORCID,Harrington Kim³,Staehr Mette¹^ORCID,Masakayan Reed¹^ORCID,Jones Jon³^ORCID,Long Thomas J.³,Ng Khong Y.⁴^ORCID,Ghoddusi Majid³^ORCID,Purdon Terence J.¹,Wang Xiuyan⁵,Do Trevor³,Pham Minh Thu³,Brown Jessica M.³^ORCID,De Larrea Carlos Fernandez¹⁶,Olson Eric³,Peguero Elizabeth⁴^ORCID,Wang Pei⁷,Liu Hong⁷,Xu Yiyang⁷,Garrett-Thomson Sarah C.⁸^ORCID,Almo Steven C.⁸,Wendel Hans-Guido⁴^ORCID,Riviere Isabelle⁵,Liu Cheng⁷,Sather Blythe³^ORCID,Brentjens Renier J.¹⁹^ORCID

Affiliation:

1. Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

2. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

3. Juno Therapeutics, A Celgene Company, Seattle, WA 98109, USA.

4. Sloan Kettering Institute, New York, NY 10065, USA.

5. Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

6. Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, 08036 Barcelona, Spain.

7. Eureka Therapeutics, Emeryville, CA 94608, USA.

8. Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

9. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Abstract

GPRC5D is an attractive target for immunotherapy of myeloma, and optimized GPRC5D-targeted CAR T cells eradicate myeloma xenografts.

Funder

National Institutes of Health

National Cancer Institute

Multiple Myeloma Research Foundation

American Society of Hematology

Leukemia and Lymphoma Society

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference35 articles.

1. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

2. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

3. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

4. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

5. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies;Current Tissue Microenvironment Reports;2024-02-03

2. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review;Blood Cancer Journal;2024-02-02

3. New Biological Therapies for Multiple Myeloma;Annual Review of Medicine;2024-01-29

4. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside;Cell Death & Disease;2024-01-15

5. Chimeric Antigen Receptor Therapy in Multiple Myeloma;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024